CA3206520A1 - Inhibitors of cgas activity as therapeutic agents - Google Patents
Inhibitors of cgas activity as therapeutic agents Download PDFInfo
- Publication number
- CA3206520A1 CA3206520A1 CA3206520A CA3206520A CA3206520A1 CA 3206520 A1 CA3206520 A1 CA 3206520A1 CA 3206520 A CA3206520 A CA 3206520A CA 3206520 A CA3206520 A CA 3206520A CA 3206520 A1 CA3206520 A1 CA 3206520A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- carboxylic acid
- pyrrolidine
- pyrimidin
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163148201P | 2021-02-11 | 2021-02-11 | |
| US63/148,201 | 2021-02-11 | ||
| PCT/US2022/016073 WO2022174012A1 (en) | 2021-02-11 | 2022-02-11 | INHIBITORS OF cGAS ACTIVITY AS THERAPEUTIC AGENTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3206520A1 true CA3206520A1 (en) | 2022-08-18 |
Family
ID=82837325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3206520A Pending CA3206520A1 (en) | 2021-02-11 | 2022-02-11 | Inhibitors of cgas activity as therapeutic agents |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240174684A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4291188A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024506904A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230144550A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116997339A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022218787A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3206520A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022174012A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112023020381A2 (pt) * | 2021-05-12 | 2023-11-21 | Boehringer Ingelheim Int | Derivados de piridina com substituintes cíclicos ligados por c como inibidores de cgas |
| CN117337292A (zh) | 2021-05-12 | 2024-01-02 | 勃林格殷格翰国际有限公司 | 作为cGAS抑制剂的具有N-连接环状取代基的吡啶衍生物 |
| WO2024035622A1 (en) * | 2022-08-10 | 2024-02-15 | Bellbrook Labs, Llc | INHIBITORS OF cGAS ACTIVITY AS THERAPEUTIC AGENTS |
| CA3267076A1 (en) * | 2022-11-09 | 2024-05-16 | Boehringer Ingelheim International Gmbh | CYCLIC PYRIDINE DERIVATIVES USED AS CGAS INHIBITORS |
| CN121248633A (zh) * | 2022-11-09 | 2026-01-02 | 勃林格殷格翰国际有限公司 | 作为cGAS抑制剂的环状苯并咪唑衍生物 |
| WO2025233174A1 (en) | 2024-05-08 | 2025-11-13 | Boehringer Ingelheim International Gmbh | Benzimidazole derivatives as cgas inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2441958T3 (es) * | 2006-07-11 | 2014-02-07 | Janssen Pharmaceutica Nv | Moduladores de benzofuro- y benzotienopirimidina del receptor de histamina H4 |
| WO2008074445A1 (en) * | 2006-12-18 | 2008-06-26 | Ucb Pharma, S.A. | Novel tricyclic and heterotricyclic derivatives, processes for preparing them, pharmaceutical compositions thereof |
| WO2013115167A1 (ja) * | 2012-01-31 | 2013-08-08 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | アムバチニブ誘導体 |
| US20200016136A1 (en) * | 2017-01-03 | 2020-01-16 | Viiv Healthcare Uk (No. 5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| WO2020142729A1 (en) * | 2019-01-04 | 2020-07-09 | BellBrook Labs | Inhibitors of cgas activity as therapeutic agents |
-
2022
- 2022-02-11 CN CN202280019484.7A patent/CN116997339A/zh active Pending
- 2022-02-11 AU AU2022218787A patent/AU2022218787A1/en not_active Abandoned
- 2022-02-11 WO PCT/US2022/016073 patent/WO2022174012A1/en not_active Ceased
- 2022-02-11 CA CA3206520A patent/CA3206520A1/en active Pending
- 2022-02-11 EP EP22753392.4A patent/EP4291188A4/en active Pending
- 2022-02-11 KR KR1020237028625A patent/KR20230144550A/ko active Pending
- 2022-02-11 US US18/275,190 patent/US20240174684A1/en not_active Abandoned
- 2022-02-11 JP JP2023548654A patent/JP2024506904A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240174684A1 (en) | 2024-05-30 |
| KR20230144550A (ko) | 2023-10-16 |
| JP2024506904A (ja) | 2024-02-15 |
| AU2022218787A1 (en) | 2023-08-17 |
| WO2022174012A1 (en) | 2022-08-18 |
| EP4291188A1 (en) | 2023-12-20 |
| CN116997339A (zh) | 2023-11-03 |
| EP4291188A4 (en) | 2025-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021345111B2 (en) | Indole derivatives as Ras inhibitors in the treatment of cancer | |
| AU2020379734B2 (en) | Ras inhibitors | |
| US20240174684A1 (en) | INHIBITORS OF cGAS ACTIVITY AS THERAPEUTIC AGENTS | |
| ES2866152T3 (es) | Derivados de tirosina amida como inhibidores de la Rho-quinasa | |
| US11337970B2 (en) | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | |
| CN107614499B (zh) | 吡啶并[3,4-d]嘧啶衍生物及其药学上可允许的盐 | |
| CA3160142A1 (en) | Ras inhibitors | |
| IL285215B2 (en) | Immunomodulators, compositions and methods thereof | |
| JP7507161B2 (ja) | 治療薬としてのcGAS活性の阻害剤 | |
| TW202321252A (zh) | 新穎螺環吡咯啶衍生的抗病毒劑 | |
| CA2679807A1 (en) | Piperidine derivatives and methods of use thereof | |
| US12427146B2 (en) | C-terminal SRC kinase inhibitors | |
| US20180305339A1 (en) | Heteroarylcarboxamide Derivatives as Plasma Kallikrein Inhibitors | |
| KR20230113289A (ko) | P2x3 억제제로서 프탈라진 유도체 | |
| US20220370431A1 (en) | C-myc mrna translation modulators and uses thereof in the treatment of cancer | |
| EP4263546B1 (en) | Dihydrofuropyridine derivatives as rho- kinase inhibitors | |
| CA3212863A1 (en) | Indoline derivatives as ddr1 and ddr2 inhibitors | |
| CN116600810A (zh) | 作为rho-激酶抑制剂的二氢呋喃并吡啶衍生物 | |
| CN115894376B (zh) | 一种芳香族酰胺类化合物、药物组合物及其用途 | |
| EP4568665A1 (en) | Inhibitors of cgas activity as therapeutic agents | |
| US12404283B2 (en) | c-MYC mRNA translation modulators and uses thereof in the treatment of cancer | |
| WO2025255442A1 (en) | Trim21-targeted compounds and uses thereof | |
| EA047132B1 (ru) | Антивирусные гетероциклические соединения | |
| BR112020013759A2 (pt) | triazóis substituídos por heterociclilamino como moduladores de proteína cinase associada a rho |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250127 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250127 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250127 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260325 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260526 |